Symbol:  Markets Quote Level II Charts News Filings Streamer

Mymetics Corp. Symbol:  MYMX Click here for a printable version Business Summary: Mymetics Corporation operates as an international biotechnology company focused on developing vaccines to combat a range of diseases. The company exploits its knowledge and intellectual property related to mucosal immunology and virosomes to develop vaccines.   Address   14, Rue de la Colombiere   Nyon CH-1260   Phone: 011-41-22-363-13-10   Fax: 011-41-22-363-13-11   Website: http://www.mymetics.com Transfer Agent   Continental Stock Transfer & Trust Co. Employees:  4 ShareHolders:  600 Founded:  1994 Domicile:  Delaware      S & P Disclaimer   Mymetics Corp. Symbol:  MYMX Click here for a printable version Mymetics Corporation operates as an international biotechnology company focused on developing vaccines to combat a range of diseases. The company exploits its knowledge and intellectual property related to mucosal immunology and virosomes to develop vaccines. It uses these approaches for a portfolio of five vaccines, of which three are in clinical trials stages. Mymetics Corporation developed its portfolio using a mixture of in-house resources, outsourcing, and collaborations with major pharmaceutical companies. Its vaccine portfolio addresses HIV, RSV, herpes, influenza, and malaria. The company's key technologies, which can be exploited across a range of other vaccines, focus on mucosal immunology and the use of virosomes as a delivery method/adjuvant. Virosome based vaccines benefit from their immunogenicity, safety profile, and stability. Mucosal immunology focuses on inducing antibody production at the body's mucosal surfaces, through which most pathogens enter the body. Mymetics Corporation plans to develop its vaccines up to the conclusion of Phase II trials, by which point partnerships with large pharmaceuticals will be entered into. The company also focuses on applying its virosomal approach and mucosal immunity approach to a range of vaccines through a combination of selective acquisitions, in-house development, partnerships, and out-licensing. It was formerly known as Hippocampe S.A. and changed its name to Mymetics Corporation on July 31, 2001. The company was founded in 1990 and is based in Epalinges, Switzerland. History:  INCORPORATED in Delaware in November 1996 as ICHOR Corp. to succeed a Pennsylvania corporation organized on July 20, 1994 as PDG Remediation, Inc., a wholly owned subsidiary of PDG Environmental, Inc. Name changed to Mymetics Corp. in July 2001.   Subsidiaries: 6543 Luxembourg S.A. Mymetics Management Sarl     Capital Expenditures, thousand. US Dollars   Year   Amount   2009   201   2008   116   2007   0   Research and Development Expenditures, thousand. US Dollars   Year   Amount   2009   9,121   2008   3,747   2007   8,734      S & P Disclaimer   Mymetics Corp. Symbol:  MYMX Click here for a printable version Management Officers Position  Jacques-Francois  Martin Chairman, President & Chief Executive Officer  Ernst  Luebke Secretary, Chief Financial Officer, Chief Accounting Officer & Treasurer  Ronald  Kempers Chief Operating Officer  Sylvain  Fleury Chief Scientific Officer  Anthony  Jessop SR VP & Investor Relations Contact Directors  Sylvain  Fleury  Ernst  Luebke  Jacques-Francois  Martin  Christian Jean-Francois Rochet  Thomas  Staehelin  Ernest M. Stern      S & P Disclaimer   Mymetics Corp. Symbol:  MYMX Click here for a printable version   Capitalization as of 03/31/2010:     Authorized Shares Outstanding Shares Common $0.01 par 495,000,000 196,263,630 Preferred $0.01 par 5,000,000 None   LONG TERM DEBT: Euro 24,783,000.   Common $0.01 par   Stockholders:  04/15/2010, 600. Transfer Agent:  Continental Stock Transfer & Trust Co.   New York , NY   OTC Bulletin Board( Primary): MYMX   Exchange Year High Low OTC Bulletin Board 2009 0.2400 0.0900 OTC Bulletin Board 2008 0.3600 0.0900 OTC Bulletin Board 2007 0.2500 0.0240 Over The Counter 2006 0.0900 0.0001 Over The Counter 2005 0.3100 0.0350 OTC Bulletin Board 2004 0.3400 0.0450 OTC Bulletin Board 2003 0.2200 0.0400 OTC Bulletin Board 2002 3.8500 0.0600 OTC Bulletin Board 2001 4.1000 1.8700 OTC Bulletin Board 2000 3.5000 0.2500   DIVIDENDS: Common $0.01 par: None.        S & P Disclaimer   Mymetics Corp. Symbol:  MYMX Click here for a printable version Annual Report   Income Statement   2009 2008 REVENUES Government Grants 13 65 Sales 136 - Interest, Dividends and Other 1 - Total Revenues 150 65 EXPENSES Directors' Fee (42) - General and Administrative Expenses (3,244) (3,693) Research and Development (6,364) (2,692) Depreciation and Amortization (226) (17) Interest Expense (2,082) (583) Change in the Fair Value of Acquisition-related Contingent Consideration 1,614 - Bank Fee (2) - Earnings before Taxes (10,196) (6,920) TAXES AND OTHER EXPENSES Provision for Income Tax 10 (18) Net Income (Loss) (10,186) (6,938) SUPPLEMENTARY INFO Basic & Diluted EPS - Continuing Operations (0.05) (0.04)   Balance Sheet   2009 2008 CURRENT ASSETS Cash 2,959 509 Receivables-other 39 6 Receivables-officer 6 8 Prepaid Expenses 34 75 Total Current Assets 3,038 598 NON CURRENT ASSETS Property and Equipment 232 76 Goodwill 6,671 - Licenses & Contracts 2,550 - In-process Research and Development 2,266 - Total Assets 14,757 674 CURRENT LIABILITIES Accounts Payable 1,540 991 Current Portion of Convertible Notes Payable to Related Parties 5,740 - Taxes and Social Costs Payable 41 25 Total Current Liabilities 7,321 1,016 NON CURRENT LIABILITIES Convertible Notes Payable to Related Parties 21,722 8,973 Convertible Notes Payable-other 2,593 - Acquisition Related Contingent Consideration 1,936 - SHAREHOLDERS' EQUITY Common Stock - Par Value 1,754 1,742 Additional Paid in Capital 20,840 20,155 Deficit Accumulated during the Development Stage (42,090) (31,904) Accumulated Other Comprehensive Income 681 685 Common Stock Issuable, Nil At December 31, 2009 and 1,000,000 At December - 7 Total Shareholders Equity (18,815) (9,315) Total Liabilities & Shareholders Equity 14,757 674      S & P Disclaimer   Mymetics Corp. Symbol:  MYMX Click here for a printable version Interim Report      Data Not Available            S & P Disclaimer   Mymetics Corp. Symbol:  MYMX Click here for a printable version Pro Forma Report      Data Not Available            S & P Disclaimer   Mymetics Corp. Symbol:  MYMX Click here for a printable version Quarterly Report Information      Quarterly Revenue, US$ Year Quarter Revenue   2010   1 40,000   2009   1 Nil   2009   2 120,000   2009   3 40,000   2009   4 50,000   2009   Full Year 150,000   2008   1 Nil   2008   2 Nil   2008   3 Nil   2008   4 110,000   2008   Full Year 110,000   2007   1 Nil   2007   2 Nil   2007   3 Nil   2007   4 Nil   2007   Full Year Nil   2006   1 Nil   2006   2 Nil   2006   3 Nil   2006   4 Nil   2006   Full Year Nil   2005   1 Nil   2005   2 Nil   2005   3 Nil   2005   4 Nil   2005   Full Year Nil     Quarterly Net Income, US$ Year Quarter Revenue   2010   1 (2,040,000)   2009   1 (4,040,000)   2009   2 (5,750,000)   2009   3 (2,410,000)   2009   4 (180,000)   2009   Full Year (14,150,000)   2008   1 (1,720,000)   2008   2 (2,570,000)   2008   3 (3,650,000)   2008   4 (3,140,000)   2008   Full Year (10,139,000)   2007   1 0   2007   2 (3,490,000)   2007   3 (1,550,000)   2007   4 (7,430,000)   2007   Full Year (12,730,300)   2006   1 (470,000)   2006   3 (540,000)   2006   Full Year (1,988,400)   2005   1 (790,000)   2005   2 (370,000)   2005   3 (380,000)   2005   Full Year (2,410,000)     Quarterly EPS, US$ Year Quarter Revenue   2010   1 (.01)   2009   1 (.02)   2009   2 (.03)   2009   3 (.01)   2009   4 Nil   2009   Full Year (.05)   2008   1 (.02)   2008   2 (.02)   2008   3 (.02)   2008   4 (.02)   2008   Full Year (.06)   2007   1 Nil   2007   2 (.03)   2007   3 (.01)   2007   4 (.04)   2007   Full Year (.09)   2006   1 Nil   2006   2 Nil   2006   3 (.01)   2006   4 Nil   2006   Full Year (.03)   2005   1 (.01)   2005   2 (.01)   2005   3 Nil   2005   4 (.01)   2005   Full Year (.04)      S & P Disclaimer